Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 15/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 15/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3856501 | 0.88 | TAS2R14 (0.35) | ITGB1ITGA4ITGB3ITGA2BALDH1A1 | |
| SCHEMBL6481325 | 0.86 | ITGB1 (0.38) | ITGB1ITGA4ITGB3ITGA2BHSD11B1 | |
| SCHEMBL3868061 | 0.82 | ITGB1 (0.37) | ITGB1ITGA4ITGB3ITGA2BHSD11B1 | |
| SCHEMBL3853268 | 0.80 | P2RX7 (0.33) | ITGB1ITGA4ALDH1A1 | |
| SCHEMBL3850609 | 0.77 | ITGB1 (0.33) | ITGB1ITGA4HSD11B1 | |
| SCHEMBL3850724 | 0.77 | P2RX7 (0.33) | ALDH1A1 | |
| SCHEMBL7069676 | 0.75 | ADAMTS5 (0.43) | ALDH1A1KMT2A | |
| SCHEMBL3870518 | 0.74 | ITGB1 (0.33) | ITGB1ITGA4HSD11B1 | |
| SCHEMBL3851221 | 0.74 | TAS2R14 (0.34) | ITGB1ITGA4ALDH1A1 | |
| SCHEMBL7385520 | 0.73 | TAS2R14 (0.41) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320960-B2 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | claimed |
| US-20040014677-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-01-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014677-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | ITGB1 70/4885ITGA4 6/4885ITGB3 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.